EGFR Exon 20 Lung Cancer: Recruiting for Trials in Korea
Where should recruitment planning begin for an EGFR exon 20 insertion lung cancer trial? Start with the pathway that identifies the right molecular alteration, establishes the relevant treatment setting and brings a potentially eligible patient to an investigator at the appropriate time. A hospital’s overall lung cancer volume cannot answer those questions on its own.
The final overall survival analysis from PAPILLON, presented at the World Conference on Lung Cancer in Seoul in September 2026, provides a timely reason to revisit this challenge. It is a clinical research development, rather than an announcement of a new Korean approval. For pharmaceutical teams, the practical question is how to connect evolving treatment evidence with a recruitment plan that reflects the intended study population. Georgetown University announcement
For a trial in Korea, that means examining molecular testing, eligibility review, referral and screening as one connected process. The discussion below separates reported clinical findings from practical planning recommendations. These recommendations are not universal regulatory requirements: the protocol, investigator judgment and applicable institutional procedures remain decisive.
Book a Free Korea Trial Consultation →
Want the full picture behind these findings? Download our 2026 Clinical Trials CRO Selection Survey Report for the complete data, red flags, and strategic recommendations.
What PAPILLON’s Final Results Mean for Recruitment Planning
PAPILLON compared amivantamab plus chemotherapy with chemotherapy in previously untreated advanced non-small cell lung cancer, or NSCLC, with EGFR exon 20 insertion mutations. Final median overall survival was 34.3 versus 27.9 months. The difference was not statistically significant: hazard ratio 0.87, 95% confidence interval 0.66–1.14, P=.307. PAPILLON study information
The result should therefore not be described as proof of an overall survival benefit. Subsequent treatment and crossover complicate interpretation, but should not be presented as the established sole explanation for the outcome. Crossover-adjusted analyses also need to be distinguished from the randomized comparison rather than used to replace its conclusion. IASLC conference reporting
For a development team, the next question is operational: which patients would a proposed trial actually seek to enroll? A first-line study and a study after disease progression may address the same molecular subgroup while requiring different identification and screening pathways. A site’s aggregate count of mutation-positive patients does not establish feasibility for both.
A useful feasibility assessment connects the proposed eligibility criteria with the way patients move through care. Teams should examine the intended treatment line, permitted previous therapies and other protocol conditions before treating a patient estimate as relevant. Performance status, organ function and central nervous system disease may also require review where the protocol specifies them. These are planning questions, not a substitute for investigator assessment.
Local treatment access must be checked separately. An international presentation does not establish Korean approval, reimbursement or availability at an individual hospital. Recruitment assumptions should reflect the treatment environment at the time the study is planned, with uncertainty documented where access or practice has not been confirmed.
Instead of asking only how many lung cancer patients a center treats, pharmaceutical teams can ask how many recently identified exon 20 insertion cases fit the proposed treatment setting. The reporting period and basis for that estimate matter. A historical patient count, a current clinic population and a protocol-filtered estimate are different measures and should be described accordingly.
Competing studies also deserve a specific review. Two trials involving EGFR may not seek the same patients, while two trials with similar biomarker and treatment-line criteria may overlap substantially. Reviewing that overlap is more informative than counting every lung cancer study at a center. Where information is incomplete, the recruitment plan should identify the unresolved question instead of disguising it as a precise forecast.
Building a Screening Pathway Around Molecular Testing
In this article, “EGFR exon 20” refers specifically to exon 20 insertion mutations. It does not mean every alteration located in exon 20. Recruitment records need enough detail to determine whether the reported variant matches the protocol definition; a general label such as “EGFR-positive” is insufficient for that purpose.
Assay coverage is an important part of this review. Research on exon 20 insertion variants has documented differences in their detectability across testing approaches. Next-generation sequencing, or NGS, can support broader variant identification, but the actual panel and its validated coverage still matter. It is inappropriate to assume that every polymerase chain reaction, or PCR, assay is inadequate or that every NGS test is automatically sufficient. Original detectability research
A Korean observational study also examined molecular identification in this population. Its findings support reviewing the testing pathway, but an institutional research cohort should not be treated as a national prevalence estimate or a forecast of available trial participants. Published observations and a site’s current recruitment evidence serve different purposes. Korean patient study
During feasibility discussions, establish who orders testing, which laboratory performs it and how results reach the treating and research teams. If central confirmation is required, clarify whether an existing result can support initial review and what additional material is needed. The answer must come from the study’s requirements and the relevant laboratory arrangements, rather than an assumption that every patient needs the same additional procedure.
Specimen readiness belongs in that conversation. Teams can ask whether available material can be assessed, which documentation accompanies it and who coordinates transfer when permitted. If another sample or procedure is necessary, medical appropriateness, protocol requirements and the relevant consent process must take priority over recruitment convenience.
Variant nomenclature can create a separate review question. Different report descriptions may require expert assessment to determine whether they refer to the same alteration. Research has highlighted the importance of consistent nomenclature for exon 20 insertions. Operationally, ambiguous reports should have a defined route to an investigator or laboratory specialist rather than being interpreted informally by recruitment staff. Nomenclature research
The recruitment record should also preserve the distinction between successive stages. A patient with an identified alteration is not automatically medically eligible, willing to participate or ready to enroll. Tracking molecular identification, eligibility review, consent, screening and enrollment separately helps prevent one stage from being reported as if it were the next.
Timing should be evaluated using current local information. A turnaround figure from a publication cannot safely be assigned to every Korean laboratory or center. Ask about the individual steps: specimen preparation, transfer, analysis, report availability and investigator review. This makes it possible to identify an operational delay without assuming that the assay itself is always the limiting factor.
Clear handoffs are particularly useful when several teams handle the same case. A testing result may be available while the person responsible for reviewing it has not yet been identified. Agreeing on responsibility and an appropriate escalation process can make the pathway more transparent without creating unrealistic promises about screening speed.
Patient care comes first throughout this process. Recruitment planning should not depend on delaying indicated care while a research pathway is completed. Participation must remain voluntary, and confirmation of the molecular alteration should never be treated as consent or as a commitment to enroll.
Turning Korean Site Feasibility into a Practical CRO Plan
Site selection should test whether the required pathway can operate, rather than rely only on reputation or overall oncology activity. It is useful to understand how the treating team, pathology or molecular laboratory, research nurses and study coordinators work together. This provides context for the patient estimates a center supplies.
Every estimate should have a clear basis. Ask whether it represents patients identified during a historical period, patients currently under care or cases assessed against the proposed protocol. When information is combined across departments or referral routes, consider potential duplicate counting. An unverified projection should remain a projection, not become a confirmed track record through repetition.
Referral arrangements can also be relevant to a small biomarker-defined population. However, the existence of a professional network does not establish a functioning screening process. Clarify who receives a referral, what information is required, when an investigator can review it and which institutional permissions and privacy procedures apply.
Referral volume and enrollment potential are not interchangeable. Travel, visit schedules, the patient’s current care arrangements and the practical burden of participation may affect whether an assessment is feasible. These considerations should inform an accurate discussion of participation, rather than become tools for pressuring patients to join a study.
The division of responsibilities with a CRO should be explicit. Teams can agree who verifies site feasibility information, coordinates operational testing questions, follows up on referral procedures and consolidates screening updates. Medical eligibility decisions remain with the investigator; operational coordination should support that decision-making process rather than replace it.
NexBridge Bio connects pharmaceutical companies with Korean CROs and supports quotation coordination and project communication.
A quotation request is more useful when it includes the study synopsis, molecular definition, treatment setting, principal eligibility conditions, testing approach and anticipated schedule. Providing only a recruitment target leaves important assumptions unresolved. Clearly marking decisions that remain open allows the CRO to explain how different assumptions affect the proposed scope.
For example, whether the study requires central confirmation is a scope question that should be settled or explicitly identified as pending. It should not be quietly inferred during quotation preparation. The same principle applies to the expected role of the CRO in site outreach, referral coordination and screening reporting.
Once the study begins, enrollment totals alone may not explain performance. Review why patients do not proceed between stages, using appropriate and permitted data. Protocol ineligibility, pending test confirmation, a patient’s decision and an operational scheduling issue call for different responses. They should not all be labeled as the same recruitment problem.
This distinction also protects clinical judgment and patient choice. A specimen-transfer delay may justify an operational correction. An investigator’s assessment that participation is inappropriate, or a patient’s decision not to participate, should not be framed as a process failure that staff must overcome.
Recruitment forecasts should evolve with evidence. When early assumptions differ from observed experience, document what was learned and revise the plan accordingly. A transparent account of eligible case flow and unresolved constraints is more useful than maintaining a monthly target that no longer has a defensible basis.
The strongest recruitment plan for an EGFR exon 20 insertion trial is therefore not a simple percentage applied to a hospital’s lung cancer population. It connects precise molecular identification, the correct treatment setting, timely investigator review and realistic site operations.
PAPILLON’s latest results provide a reason to reassess the disease and trial landscape, but they do not establish recruitment performance at any Korean center. The next practical step is to test study-specific assumptions against current site evidence and turn the findings into clearly assigned work.
Planning an EGFR Exon 20 Trial in Korea?
Before requesting Korean CRO feasibility support, organize the study synopsis, biomarker definition, treatment line and testing strategy. Separate confirmed decisions from open questions so that site assessment and quotation discussions can address the actual study requirements.
Book a Free Korea Trial Consultation →
Want the full picture behind these findings? Download our 2026 Clinical Trials CRO Selection Survey Report for the complete data, red flags, and strategic recommendations.
Frequently Asked Questions
Q1: Can total EGFR-positive patient numbers predict recruitment?
Not on their own. The estimate needs to distinguish exon 20 insertion mutations and reflect the intended treatment setting and protocol criteria. The reporting period, data source and possibility of duplicate counting should also be clear.
Q2: Does every patient need NGS testing?
This article does not prescribe a test for every patient. Review the testing methods permitted by the protocol and the assay’s validated variant coverage. Any central testing or additional confirmation requirements must be assessed for the individual study.
Q3: Did PAPILLON’s final analysis prove an overall survival benefit?
No. Median overall survival differed numerically, but the difference was not statistically significant. Descriptions of the result should preserve the distinction between a numerical difference and an established benefit.
Q4: What should be checked first at a Korean trial site?
Begin by asking whether recent, documented molecularly identified cases match the proposed study population. Then examine how test results, investigator review, referral and screening are connected in practice. Neither patient volume nor a referral network alone establishes recruitment readiness.
Q5: What should a pharmaceutical company provide for CRO feasibility review?
Provide the study synopsis, biomarker definition, treatment setting, key eligibility criteria, testing requirements, anticipated timing and requested scope. Identify unresolved decisions so that the assessment is based on explicit assumptions rather than information the CRO has had to infer.